Introduction Up to 40% of orthopaedic injuries in children require a closed reduction, almost always necessitating procedural sedation. Intravenous ketamine is the most commonly used sedative agent. However, intravenous insertion is painful and can be technically difficult in children. We hypothesise that a combination of intranasal dexmedetomidine plus intranasal ketamine (Ketodex) will be non-inferior to intravenous ketamine for effective sedation in children undergoing a closed reduction.
Methods and analysis This is a six-centre, four-arm, adaptive, randomised, blinded, controlled, non-inferiority trial. We will include children 4–17 years with a simple upper limb fracture or dislocation that requires sedation for a closed reduction. Participants will be randomised to receive either intranasal Ketodex (one of three dexmedetomidine and ketamine combinations) or intravenous ketamine. The primary outcome is adequate sedation as measured using the Paediatric Sedation State Scale. Secondary outcomes include length of stay, time to wakening and adverse effects. The results of both per protocol and intention-to-treat analyses will be reported for the primary outcome. All inferential analyses will be undertaken using a response-adaptive Bayesian design. Logistic regression will be used to model the dose–response relationship for the combinations of intranasal Ketodex. Using the Average Length Criterion for Bayesian sample size estimation, a survey-informed non-inferiority margin of 17.8% and priors from historical data, a sample size of 410 participants will be required. Simulations estimate a type II error rate of 0.08 and a type I error rate of 0.047.
Ethics and dissemination Ethics approval was obtained from Clinical Trials Ontario for London Health Sciences Centre and McMaster Research Ethics Board. Other sites have yet to receive approval from their institutions. Informed consent will be obtained from guardians of all participants in addition to assent from participants. Study data will be submitted for publication regardless of results.
Trial registration number NCT0419525.
- paediatric anaesthesia
- pain management
- paediatric A&E and ambulatory care
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
Statistics from Altmetric.com
Strengths and limitations of this study
This study employs a response adaptive trial design to overcome gaps in our current understanding of the most effective dosing combination of intranasal Ketodex.
To optimise trial efficiency, frequent assessment of the data will be used to adapt the trial to increase the number of participants receiving the more effective combination of Ketodex.
This study involved a patient engagement strategy whereby patient partners informed the eligibility criteria and outcomes, and reviewed letters of information, consent and assent.
We expect that current translation to practice may be limited by the high volume of intranasal drug required for older children unless a higher concentration of ketamine (100 mg/kg) becomes widely available.
Research nurses may become aware of group assignment and blinding will only be possible for outcome assessors.
Orthopaedic injuries comprise more than 10% of emergency department (ED) visits in children,1 2 and 25%–50% of children will sustain a fracture before the age of 16 years.3 Between 20% and 40% of extremity fractures in children require a closed reduction,4 5 often necessitating procedural sedation. The demand for procedural sedation in children outside the operating room is increasing at a rate of 10% annually.6 7 As such, the placement of an intravenous catheter for procedural sedation is extremely common. However, children rate intravenous insertion as one of the most painful hospital experiences, second only to the painful condition itself.8 intravenous insertion can be more technically difficult in children because of smaller veins9 and lack of cooperation,8 9 often leading to multiple intravenous attempts.
Intranasal medications may obviate the need for distressing intravenous placement and offer a technically easier and pain-free approach to procedural sedation.10 This may have widespread applicability in patients with difficult intravenous access, resource-limited settings, needle phobia or when experience placing an intravenous is limited. Ketamine is the most commonly used sedative agent for fracture reduction in children11 and intranasal ketamine has been found to be effective for fracture pain,10 some procedural pain,12 anaesthetic preinduction13 and diagnostic imaging.14 However, neither agent has been studied for procedural sedation to reduce fractures or dislocations. Dexmedetomidine is a central alpha 2-adrenergic receptor agonist with analgesic and anxiolytic properties and is effective for procedural anxiety in children in its intravenous form.2 15 16 A recent systematic review of intranasal dexmedetomidine in children undergoing painful procedures (dental procedures, venipuncture and laceration repair) found doses ranging from 1 to 4 mcg/kg were well tolerated and superior to conventional sedatives (oral chloral hydrate and oral and intranasal midazolam) in providing adequate sedation.17
However, procedural sedation for orthopaedic reduction may require agents with greater sedative and analgesic potency. Preliminary evidence suggests that a combination of dexmedetomidine and ketamine may be superior than either agent alone.18 19 A combination of intranasal ketamine and intranasal dexmedetomidine (‘Ketodex’) theoretically combines the analgesic efficacy of ketamine20 with the sedative efficacy of dexmedetomidine.21 However, there remains uncertainty regarding the ideal combination of these two agents. In order to provide robust evidence supporting an alternate approach that precludes the need for an intravenous in children undergoing sedation, a response-adaptive Bayesian design will be used to determine the most effective combination of Ketodex and to test our hypothesis of whether this combination is non-inferior to intravenous ketamine.
Methods and analysis
This is a six-centre, four-arm, randomised, blinded, double-dummy, controlled, parallel group, adaptive dose-finding, non-inferiority, phase II/III trial. The trial will determine whether intranasal Ketodex is non-inferior to intravenous ketamine for children undergoing procedural sedation and analgesia determine the optimal dosing combination for intranasal Ketodex. The study protocol is reported using the SPIRIT-PRO reporting guidelines.22
This study will be conducted in six paediatric EDs across Canada: (1) Children’s Hospital at London Health Sciences Centre (London, Ontario) (coordinating site); (2) Stollery Children’s Hospital (Edmonton, Alberta); (3) BC Children’s Hospital (Vancouver, British Columbia); (4) Winnipeg Children’s Hospital (Winnipeg, Manitoba); (5) CHEO (Ottawa, Ontario); and (6) McMaster Children’s Hospital (Hamilton, Ontario). The annual ED census for recruiting centres ranges from 30 000 to 70 000 patient visits.
Children will be eligible if they meet all of the following criteria: (1) provision of signed and dated informed consent form; (2) stated willingness to comply with all study procedures and availability for the duration of the study; (3) deemed by treating physician to require procedural sedation; (4) aged 4–17 years; (5) weighing up to and including 60 kg; (6) one of the following injuries: forearm fracture, metacarpal or phalangeal fracture, or dislocation of a shoulder or elbow; (7) closed reduction expected to take no more than 5 min to reduce (as determined by the procedure physician and not including cast or splint application); and (8) both nares are fully patent. Exclusion criteria are listed in table 1.
Interventions and permissible cointerventions
Eligible participants will be randomised to intranasal Ketodex or intravenous ketamine with a 3:2 allocation ratio. Participants receiving intranasal Ketodex will be further adaptively randomised to three alternative combinations where the randomisation ratio is proportional to the posterior probability that a combination is optimal in terms of providing adequate sedation. A double-dummy approach will be used to overcome the possibility of unmasking due to perceptible differences in interventional routes. This involves each participant receiving both an intranasal and intravenous intervention, only one of which is the real drug. Both intranasal and intravenous interventions will be administered through any of the following:
Dexmedetomidine (Pfizer, Kirkland, Quebec), single dose, 4 mcg/kg (0.04 mL/kg) of 100 mcg/mL solution, maximum of 200 mcg (2 mL), then ketamine (Sandoz, Mississauga, Ontario), single dose, 2 mg/kg (0.04 mL/kg) of 50 mg/mL solution, maximum of 200 mg (4 mL) (D4K2), both delivered intranasally using a mucosal atomiser device (MAD) and divided to both nares and 0.9% normal saline 0.03 mL/kg delivered intravenously to a maximum of 2 mL.
Dexmedetomidine (Pfizer), single dose, 3 mcg/kg (0.03 mL/kg) of 100 mcg/mL solution, maximum of 200 mcg (2 mL), then ketamine (Sandoz), single dose, 3 mg/kg (0.06 mL/kg) of 50 mg/mL solution, maximum of 300 mg (6 mL) (D3K3), both delivered intranasally using MAD and divided to both nares and 0.9% normal saline 0.03 mL/kg delivered intravenously to a maximum of 2 mL.
Dexmedetomidine (Pfizer), single dose, 2 mcg/kg (0.02 mL/kg) of 100 mcg/mL solution, maximum of 200 mcg (2 mL), then ketamine (Sandoz), single dose, 4 mg/kg (0.08 mL/kg) of 50 mg/mL solution, maximum of 400 mg (8 mL) (D2K4), both delivered intranasally using MAD and divided to both nares and 0.9% normal saline 0.03 mL/kg delivered intravenously to a maximum of 2 mL.
Ketamine, single dose, 1.5 mg/kg (0.03 mL/kg) of 50 mg/mL solution delivered intravenously, to a maximum of 100 mg (2 mL) and two aliquots of 0.9% normal saline in three possible combinations: (1) 0.04 mL/kg (max 2 mL) then 0.04 mL/kg (max 4 mL) (placebo D4K2), (2) 0.03 mL/kg (max 2 mL) then 0.06 mL/kg (max 6 mL) (placebo D3K3), and (3) 0.02 mL/kg (max 2 mL) then 0.08 mL/kg (max 8 mL) (placebo D2K4), delivered intranasally using MAD and divided to both nares.
Participants will be positioned in a recumbent supine position at 45°. Each pair of sprays will be separated by at least 60 s. The physician or their designate must administer the intravenous intervention 30–40 min after the intranasal dexmedetomidine/saline sprays. The research or bedside nurses will administer intranasal interventions, and the physician or their designate will administer intravenous interventions (figure 1).
All participants will receive continuous cardiorespiratory monitoring, consisting of five-lead continuous ECG, oxygen saturation and blood pressure, with consideration of capnography. This will commence immediately prior to administration of the intervention and will continue until the participant is awake.
The treating physician will not be permitted to prescribe any sedative, anxiolytic or analgesic cointervention within 15 min of the study intervention. Analgesics for pain and antiemetics may be given at any time at the discretion of the clinician or nurse outside the procedural sedation period. Anxiolytics for emergence agitation or anxiety may be given following the closed reduction. Any prescribed home or over-the-counter medications may be given at any time during the index visit with the exception of sedatives.
Rescue sedation may be provided if, after 1 min following the intravenous intervention, either of the following conditions are met: (1) the participant is still responding to surroundings or (2) procedure has begun and the participant’s vocalisations are consistent with pain, or the participant is withdrawing or localising to pain.
Randomisation and allocation concealment
Randomisation will be performed in two stages as follows:
First, the pharmacy at each site will randomise participants in a 3:2 allocation ratio to intranasal Ketodex or intravenous ketamine and will adapt a previously published design.23 This stage will be stratified by site and will be randomised in a block size known only to the statistical team.
Second, participants in the Ketodex group will be adaptively randomised using REDCap to three possible combinations of intranasal ketamine and intranasal dexmedetomidine in a 1:1:1 ratio for the first 150 participants: 2 mg/kg intranasal ketamine+4 μg/kg intranasal dexmedetomidine or 3 mg/kg intranasal ketamine+3 μg/kg intranasal dexmedetomidine or 4 mg/kg intranasal ketamine+2 μg/kg intranasal dexmedetomidine). After the first 150 participants, the randomisation ratio will be adapted after every 50 recruited participants. The allocation ratio will be set equal to the posterior probability that a given dose is the most effective given all the available data at each interim analysis (200, 250, 300 and 350 participants). The number of participants randomised to each combination will be adapted throughout the trial to increase the number of participants receiving the more effective intranasal Ketodex combination. Intranasal Ketodex combinations will be dropped if the probability that this dose is optimal falls below 0.05. Two combinations will be dropped if there is a greater than 95% chance that a single combination is optimal. If all dose combinations have a probability of being the most effective of less than 50% after 250 participants have been enrolled in the trial, the safety profile will be evaluated to determine the most promising combination in conjunction with the data safety monitoring board (DSMB). This will be used as the single intranasal Ketodex comparator for the remainder of the trial.
NB. Participants in the intravenous ketamine group will also undergo the second stage of randomisation but will receive saline in the identical volumes to the active drug, that is, two aliquots of 0.9% normal saline in three possible combinations: (1) 0.04 mL/kg (max 2 mL) then 0.04 mL/kg (max 4 mL), (2) 0.03 mL/kg (max 2 mL) then 0.06 mL/kg (max 6 mL) and (3) 0.02 mL/kg (max 2 mL) then 0.08 mL/kg (max 8 mL).
The allocation tables will be generated by the data coordinating centre (DCC) statistician at the Women and Children’s research Institute at the University of Alberta using R. The allocation tables across the different dose combinations will be updated at 150, 200, 250, 300 and 350 participants. An independent statistician will validate the tables and the code that was used to create them. The tables will then be provided to site pharmacies for creation of the study kits, ensuring that study staff remain blinded. Site pharmacies will prepare identically appearing study kits containing the intravenous and intranasal interventions in accordance with the allocation tables.
Blinded parties include the participant, caregiver, research nurse videotaping the procedure and outcome assessor. Participants should not be aware of group assignment because 0.9% normal saline, dexmedetomidine and ketamine solutions are odourless, colourless and tasteless. Kits containing the interventions will be identically appearing, differing only by a study number. However, differences in onset of sedation between intravenous ketamine and intranasal Ketodex risk unblinding the sedating physician, research nurse and outcome assessor. To minimise this risk, the intravenous intervention will be given 30–40 min following the intranasal dexmedetomidine/saline sprays due to intranasal dexmedetomidine’s longer onset of action (20–30 min)21 versus intravenous ketamine (1 min).24 To increase the probability that both components of intranasal Ketodex are clinically effective at the same time, a green-labelled vial containing intranasal dexmedetomidine or saline will be administered first, followed by a white-labelled vial containing either intranasal ketamine or saline.
The research nurse will record the video of the participant’s entire body (including the face) starting immediately prior to the closed reduction and continuing until the reduction is complete. Two trained and independent outcome assessors remote from the clinical encounter and unaware of the study objectives will score sedation using the Paediatric Sedation State Scale (PSSS) (and determine the primary outcome) every 30 s for the entire length of the video. The second outcome assessor will score a randomly selected 25% sample of the participant videos to generate an inter-rater agreement. Flags will alert the outcome assessor when the closed reduction procedure is started and completed.
The DSMB may request unblinding directly from the DCC statistician. Urgent unblinding may be done if the participant suffers an adverse event (AE), the management of which is predicated on knowing the group assignment. The research nurse will log into a secure web-based unblinding system with REDCap, where the study medication will be revealed only to the treating physician. Thus, caregivers, children and research staff, including outcome assessors, will remain blinded.
Potential participants will be screened and enrolled consecutively during the hours of research nurse availability (≤8 hours/day, 7 days/week). Families will provide verbal consent for eligibility screening by the research nurse. For patients who pass initial screening, the research nurse will confirm eligibility with the ED physician or their designate (any clinician who has the capacity to assess, manage and discharge a patient). If eligibility is confirmed, the research nurse will explain the study protocol and seek informed consent (and assent when appropriate) (see online supplemental files 1 and 2). Mature minor consent forms will be available for both accompanied and unaccompanied minors. Research nurse will record basic demographic features and eligibility criteria of all children with an orthopaedic injury requiring procedural sedation during their availability, whether randomised or not, to assess for enrolment bias.
All outcomes and endpoints apart from the determination of adequate sedation (the primary outcome) will be collected by the research nurse and recorded using REDCap and a Wi-Fi-enabled iPad device.
The research nurse will record a video of the participant’s closed reduction using a Canon VIXIA HF R700 camcorder mounted on a tripod. Once data collection is completed, the video file will be uploaded onto a shared drive, which will be accessed only by the two outcome assessors. Training for the outcome assessors will consist of a 1-hour PowerPoint presentation that outlined PSSS scoring and hands-on training using videos of 25 children who underwent procedural sedation.
Following the application of a cast or splint, the research nurse will obtain satisfaction scores from the sedating provider, bedside nurse and participant. Research nurses will be trained on the recognition and definition of all expected and unexpected AEs.24–26 The research nurse will record AEs from the medical record and queries from healthcare staff during sedation and recovery. Uncertainty will be clarified with the sedating physician. All AEs will be recorded except for expected physiological effects of ketamine such as elevated blood pressure and heart rate, increased oral secretions, nystagmus, enhanced skeletal muscle tone, flushing and confusion on wakening.27 28
When the participant is awake, the research nurse will ask participants to rate their nasal irritation related to the intranasal sprays using the FPS-R. To detect maladaptive behaviours following discharge, the caregiver will be surveyed either by telephone or automated email survey administered by REDCap 24–48 hours following discharge using the Posthospital Behaviour Questionnaire (PHBQ).29 A schedule of activities is shown in table 2.
The primary efficacy outcome is adequate sedation for the duration of the procedure as we believed this to be the most salient patient-oriented outcome. Sedation will be deemed ‘adequate’ if all of the following conditions are met: (1) a PSSS score of 2 or 3 for the duration of closed reduction; (2) no additional medication is given during the procedure for the purpose of sedation; and (3) the patient did not actively resist, cry or require physical restraint for completion of the procedure. The PSSS (figure 2) is an instrument developed for assessment of sedation in children aged 1–7 years undergoing laceration repair using video scoring.30 The PSSS is scored from 0 to 5, with a higher number indicating a lesser degree of sedation. The PSSS assesses pain as well as oversedation and undersedation. Adequate sedation is a score of 2 or 330 and represents a level of sedation that correlates with a lack of pain, distress or oversedation or undersedation; optimal for procedural sedation as outlined by the Joint Commission, the American Academy of Paediatrics31 and the American Society of Anaesthesia.32
Secondary outcomes include the following:
Length of stay is the time interval between triage and discharge.
Time to wakening is the time interval between the first pair or intranasal sprays to the first PSSS score of >3 postclosed reduction as determined by the research nurse.
AEs are based on Health Canada reporting standards (see online supplemental file 3). They include nasal irritation, which will be assessed using the FPS-R33 immediately prior to discharge and maladaptive behaviours 24–48 hours postrecovery, which will be assessed using the PHBQ.29 The FPS-R will be administered using an iPad, and the PHBQ will be administered through an automated email survey from REDCap or by telephone. All AEs will be classified according to the Medical Dictionary for Regulatory Activities (MedDRA).
Other endpoints are listed in table 1.
Two surveys were disseminated to over 200 paediatric and general emergency physicians across Canada. We presented the case of a 5-year-old girl meeting the study’s inclusion criteria. We asked respondents to choose single-dose intravenous or intranasal ketamine for procedural sedation and to specify the largest percentage of children who failed intranasal sedation they would be willing to accept in order to routinely attempt the intranasal route first. From these surveys, the average non-inferiority margin η was 17.8%. To determine a maximum sample size, we used the Average Length Criterion (ALC) for Bayesian sample size estimation.34 This method selects the smallest sample size required to ensure that the 95% posterior credible interval has an average length of 0.07. We also considered four alternative randomisation strategies of intravenous ketamine to intranasal Ketodex: 1:4, 3:7, 2:3 and 1:1. The ALC determines the maximum sample size and the randomisation ratio between intravenous ketamine and intranasal Ketodex. First, we selected the smallest sample size for which the average length of the 95% posterior credible interval fell below 0.07. For this sample size, we then selected the randomisation ratio that led to the most balanced trial, provided the average length of the 95% posterior credible interval remained below 0.07. We used 2000 simulations to estimate the average posterior credible interval; the posteriors were approximated using 2000 simulation, for sample sizes increasing in increments of 10, across all four randomisation regimes. Based on this analysis, the sample size for the Ketodex trial is 410 patients randomised at a 3:2 ratio of intranasal Ketodex to intravenous ketamine.
The results of both per protocol and intention to treat analyses will be reported for the primary outcome, with the intention-to-treat analysis being taken as the primary analysis. Demographic data will be summarised using frequencies and percentages for categorical variables and means, medians, SD and IQRs for continuous variables. Length of stay, onset of sedation and duration of sedation will be analysed using a linear dose–response model to estimate the mean duration for the optimal intranasal Ketodex combination. Adverse effects (AEs) will be analysed using a logistic dose–response model for intranasal Ketodex and a binomial distribution for intravenous ketamine. We will use logistic regression to investigate the interaction between baseline pain, measured using the FPS-R, considered as a continuous variable, and treatment effect. All inferential analyses will be undertaken using a Bayesian framework with significance declared based on posterior probabilities. We will use 95% high-density posterior credible interval estimates to report treatment effect estimates. Due to the likelihood principal, no adjustments will be made for multiplicity and type I error will be controlled through prior specification. Descriptive statistics will be reported as frequencies and percentages for discrete variables and means, medians, SD and IQRs for continuous variables. A statistical analysis plan is being published separately and includes comprehensive details of prior specification. The primary analysis will determine if the optimal intranasal Ketodex combination is non-inferior to intravenous ketamine. All other analyses will test for superiority of intranasal Ketodex. The primary analysis of the primary outcome will involve logistic regression to model the dose response relationship for the combinations of intranasal Ketodex. The optimal dose combination will be the dose with the maximum posterior expected probability of adequate sedation. We will then consider whether this optimal dose is non-inferior to intravenous ketamine by computing the posterior probability of non-inferiority. If the probability of non-inferiority is above 0.97, then we will declare that intranasal Ketodex is non-inferior to intravenous ketamine. This gives a power of 0.92 to detect that the probability of adequate sedation is equal to 0.9 and a type I error rate of 4.3%. Secondary outcomes will be assessed using appropriate dose response models for intranasal Ketodex and posterior updating for intravenous ketamine. An additional analysis will investigate the interaction between baseline pain and the treatment effect.
We will undertake seven interim analyses, at increments of 50 enrolled participants. Safety outcomes will be reviewed by the DSMB at each interim analysis. The decision to stop the trial for safety reasons will at the discretion of the DSMB. Due to the ‘unbalanced’ recruitment, the DSMB will not be blinded to treatment assignment. We will not undertake comparative effectiveness analyses at the interim analyses and will not stop for efficacy or futility.
If the percentage of missing data is ≤5%, we will undertake a per protocol analysis. If the percentage of missing data is >5%, we will use a full Bayesian analysis to jointly model the missing data model and the outcome model.
Patient and public involvement
The study team’s patient engagement partner (SH) led a group of four patient partners who informed the trial’s eligibility criteria, burden of interventions and outcomes. From their experiences as caregivers of children who visited a healthcare setting, they reviewed and provided feedback on the content of the recruitment pitch, letters of information, consent and assent. Results will not be directly disseminated to participants but will be provided on request or through access to the trial’s website (www.kidscantrials.ca/ipctnetwork).
Data management services will be provided by the Women and Children’s Health Research Institute (WCHRI) DCC. Study data will be entered and managed using REDCap tools hosted and supported by WCHRI. WCHRI’s REDCap installation is a electronic, web-based data capture system validated in accordance with section C.05.012 of the Health Canada Part C, Division 5 of the Food and Drug Regulations, ‘Drugs for Clinical Trials Involving Human Subjects’.
Data will be entered directly into the study database using a Wi-Fi-enabled encrypted iPad. In the case of a technical failure, data will be collected on paper and then transcribed into REDCap by the research nurse or site coordinator.
The study participant’s contact information will be securely stored at each clinical site for internal use during the study. At the end of the study, all records will continue to be kept in a secure location for as long a period as dictated by the reviewing REB, institutional policies or sponsor requirements. For Health Canada-regulated trials, this is 25 years. Individual participants and their research data will be identified by a unique study identification number.
Monitoring for quality and regulatory compliance will be performed by the University of Alberta’s Quality Management in Clinical Research (QMCR) office. QMCR is an independent unit housed within the university’s central administration that provides arms-length review of all University of Alberta sponsored trials, at least three times per year. Details of clinical site monitoring will be documented in a clinical monitoring plan. This trial will also be monitored federally by Health Canada (approval number HC6-24-c230863) and an institutional level by site-specific clinical research oversight bodies, as per local requirements.
Safety oversight will be under the direction of the DSMB, which will function independently of the investigators. This committee will be chaired by Dr Garth Meckler and is composed of five individuals with expertise in trial methodology, epidemiology, biostatistics and paediatric emergency medicine. The DSMB will meet at least semiannually to assess safety and efficacy data and will operate under the rules of an approved charter/terms of reference. Interim analyses will be undertaken at intervals of 50 enrolled participants. The DSMB will, in collaboration with the trial steering committee, establish safety stopping rules prior to trial initiation. The DSMB will be provided with a masked comparison between treatment groups with respect to the safety endpoints at the intervals of their choosing. At the DSMB’s request, they can receive posterior credible intervals or predictive probabilities. They can further request unmasking. The decision to stop the trial for safety reasons will be left to the discretion of the DSMB.
The most important limitation of our work is our inability to procure a higher concentration of ketamine for intranasal sprays. This will result in a large number of sprays for heavier participants. Although these individuals may be more compliant with a greater number of sprays, this may impact the external generalisability of the work and translation into clinical practice. Some countries (Australia and the USA) have access to higher concentrations of intranasal ketamine (100 mg/mL) for clinical use, which may increase the clinical uptake of our findings.
Ethics and dissemination
Ethics approval was obtained from Clinical Trials Ontario (London Health Sciences Centre and McMaster Research Ethics Board #1987). The other participating sites have yet to receive ethics approval from their institutions. All protocol amendments will be submitted for approval to Health Canada before being communicated to each site. All protocol amendments will be added to the clinicaltrials.gov registration and implemented only after Health Canada and REB approval. All study participants, or their caregivers, will be notified if any new findings become available, which may be in the best medical interest of the study participant or may impact their willingness to continue participation in the study.
While long-term risks are not expected, immediate risks may occur. In terms of safety of intranasal dexmedetomidine, Kim et al35 synthesised the evidence for preoperative intranasal dexmedetomidine in 11 trials of 1097 children and reported no occurrences of nausea, vomiting, hyperglycaemia, delirium or serious adverse effects. There have been no reports of mucosal irritation, ulceration or bleeding with intranasal administration.17 36 All AEs will be classified according to MedDRA – a multilingual standardised international medical terminology dictionary used for ‘regulatory communication and evaluation of data pertaining to medicinal products for human use.’37 Serious adverse events (SAEs) will be defined based on the Quebec guidelines26 (see online supplemental file 3). Expected and unexpected SAEs will be reported to the DSMB and Health Canada, respectively.
The study team plans to publish results in a high-impact, peer-reviewed journal and present the findings at local research days, network meetings and societal conferences. The statistical analysis plan and design paper will be published separately. Additional dissemination strategies will be developed in conjunction with our patient partners and research team. The statistical code and dataset can be made available on request.
The authors would like to acknowledge the iPCT SPOR administrative staff and our patient partners, who provided valuable support and input on the study design and documents. The following are the members of the KidsCAN PERC Innovative Pediatric Clinical Trials Ketodex Study Team: Dr Eleanor Pullenayegum, David Rios, Karly Stillwell, Shana Rimmer, Rick Watts, Tannis Erickson, Chelsea Bowkett, Carolyn Shimmin, Brendon Foot, Chelsea Bowkett, Candace McGahern, Redjana Carciurmaruj, Patricia Candelaria, and Jeannine Schellenberg.
Contributors NP is the principal investigator. He developed and revised the protocol, drafted the manuscript, and will oversee study operations. KC is a research coordinator. He contributed to study design and drafting of the manuscript. He will be responsible for all study operations. DB, SS, MB, AK, QD, VS and SA are site leads at their respective institutions. They contributed to study design and drafting of the protocol and manuscript. They will be responsible for study operations at their sites. MO and PP contributed to the adaptive study methodology and drafting of the manuscript. AH and MY created the statistical analysis plan and contributed to drafting of the manuscript. TK is the nominated principal investigator for the iPCT-SPOR network. He reviewed and revised the manuscript. SH is a patient engagement partner. She led a group of other patient partners who provided input into patient-oriented outcomes, intervention administration and letters of information, consent and assent. All authors have approved the final version of the manuscript. None of the authors have financial or other conflicts of interests as they pertain to this study and its involved recruitment sites.
Funding This work is supported by an Innovative Clinical Trials Multi-year Grant from the Canadian Institutes of Health Research (funding reference number MYG-151207, 2017–2020), as part of the Strategy for Patient-Oriented Research and the Children’s Hospital Research Institute of Manitoba (Winnipeg, Manitoba), the Centre Hospitalier Universitaire Sainte-Justine (Montreal, Quebec), the Department of Pediatrics, University of Western Ontario (London, Ontario), the Alberta Children’s Hospital Research Institute (Calgary, Alberta), the Women and Children’s Health Research Institute (Edmonton, Alberta), the Children’s Hospital of Eastern Ontario Research Institute Inc. (Ottawa, Ontario) and the Hospital for Sick Children Research Institute (Toronto, Ontario). This study is sponsored by The Governors of the University of Alberta (Suite 400, 8215–112 Street, Edmonton, Alberta, Canada T6G 2C8). Neither the study sponsor nor funders have any role in the collection, management, analysis or interpretation of data; writing of the report; or the decision to submit the report for publication. Additional support was received from the Physicians Services Incorporated Foundation, Academic Medical Organization of Southwestern Ontario, Ontario Ministry of Economic Development, Job Creation and Trade, and the Children’s Health Foundation of the Children’s Hospital, London Health Sciences Foundation.
Competing interests None declared.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.